A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07003321 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2025-12-18
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Conditions
Interventions
- DRUG
-
HRS-4508 tablet
HRS-4508 tablet
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-12
- Primary Completion
- 2027-09-30
- Completion
- 2028-07-31
Countries
- China
Study Locations
More Related Trials
-
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
NCT04354961 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
NCT06110663 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT06461156 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of SHR-1316 and Fluzoparib(SHR-3162) in Small Cell Lung Cancer Patients
NCT04041011 ·Status: COMPLETED ·Phase: PHASE1
-
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
NCT04500704 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03240393 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
NCT05900219 ·Status: UNKNOWN ·Phase: PHASE2
-
HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
NCT06822998 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
NCT02981108 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
HS-IT101 Injection for Advanced NSCLC
NCT07105176 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT05015608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
NCT05552781 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
NCT04685070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT06417008 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
NCT04207775 ·Status: COMPLETED
-
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
NCT04959981 ·Status: COMPLETED ·Phase: PHASE1
-
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
NCT05117658 ·Status: UNKNOWN ·Phase: PHASE2
-
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
NCT07231068 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
NCT06786208 ·Status: NOT_YET_RECRUITING
-
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
NCT05284539 ·Status: RECRUITING ·Phase: PHASE2
-
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00085280 ·Status: COMPLETED ·Phase: NA
-
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
NCT05086666 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2